StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke
worldwide, including Japan, the United States, and Europe. It aims to evaluate the effectiveness and safety of administering Redasemtide to 627 patients with acute ischemic stroke, aged 18 years and above, within 25 hours of symptom onset.